Drug Type Biosimilar, Fusion protein |
Synonyms Aflibercept Biosimilar (Formycon AG), 阿柏西普生物类似药(Formycon AG), FYB-203 + [3] |
Target |
Mechanism PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (28 Jun 2024), |
Regulation- |
Start Date20 Sep 2024 |
Sponsor / Collaborator |
Start Date21 Jul 2020 |
Sponsor / Collaborator |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Myopic choroidal neovascularization | EU | 13 Jan 2025 | |
Myopic choroidal neovascularization | EU | 13 Jan 2025 | |
Myopic choroidal neovascularization | IS | 13 Jan 2025 | |
Myopic choroidal neovascularization | IS | 13 Jan 2025 | |
Myopic choroidal neovascularization | LI | 13 Jan 2025 | |
Myopic choroidal neovascularization | LI | 13 Jan 2025 | |
Myopic choroidal neovascularization | NO | 13 Jan 2025 | |
Myopic choroidal neovascularization | NO | 13 Jan 2025 | |
Diabetic macular oedema | US | 28 Jun 2024 | |
Diabetic Retinopathy | US | 28 Jun 2024 | |
Retinal vein occlusion-related macular edema | US | 28 Jun 2024 | |
Wet age-related macular degeneration | US | 28 Jun 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dystrophy, Macular | NDA/BLA | CA | 01 Jan 2025 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |